Theriva Biologics, Inc. recently disclosed the outcomes of a Type D meeting with the U.S. Food and Drug Administration (FDA), outlining details regarding the design of a Phase 3 clinical study ...

The evidence for the authors' claims is convincing, combining state-of-the-art conditional gene deletion in the mouse lens with histological and molecular approaches. This work should be of great ...

The agreement covers the manufacturing of standard BCG (sBCG) that is currently approved for use outside the U.S., as well as a next-generation recombinant BCG (iBCG) undergoing testing ...

Førsvoll and Oymar 5 Increased IL-1 β, IL-6, TNF-α levels Inflammation Stojanov et al 9 Increased IL-6, INF-γ, IL-1β, TNF-α levels; reduced IL-4 levels Inflammation Brown et al 11 ...